PBAC Public Summary Documents - March 2019
Page last updated: 19 July 2019
Public Summary Documents relating to the March 2019 PBAC meeting.
- Abemaciclib: Tablet 50 mg, Tablet 100 mg, Tablet 150 mg; Verzenio®
- Alectinib: Capsule 150 mg; Alecensa®
- Alirocumab: Injection 75 mg in 1 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen; Praluent®
- Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin®
- Benzathine Benzylpenicillin: Injection 517 mg in 1.17 mL single use pre-filled syringe; Bicillin L-A®
- Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Avastin®
- Blinatumomab: Powder for I.V. infusion 38.5 micrograms; Blincyto®
- Botulinum Toxin Type A: Lyophilised powder for injection 100 units; Botox®
- Budesonide: Capsule (modified release) 3 mg; Budenofalk®
- Budesonide: Capsule (modified release) 3 mg; Entocort®
- Buprenorphine: Injection 8 mg in 0.16 mL pre-filled syringe, Injection 16 mg in 0.32 mL pre-filled syringe, Injection 24 mg in 0.48 mL pre-filled syringe, Injection 32 mg in 0.64 mL pre-filled syringe, Injection 64 mg in 0.18 mL pre-filled syringe, Injection 96 mg in 0.27 mL pre-filled syringe, Injection 128 mg in 0.36 mL pre-filled syringe; Buvidal®
- Buprenorphine: Injection (modified release) 100 mg in 0.5 mL pre-filled syringe, Injection (modified release) 300 mg in 1.5 mL pre-filled syringe; Sublocade®
- Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
- Calcium: Tablet, chewable, 500 mg (as carbonate); Cal-500®
- Certolizumab Pegol: Injection 200 mg in 1 mL pre-syringe pen, Solution for injection 200 mg in 1 mL pre-filled pen; Cimzia®
- Clostridium Botulinum Type A Toxin – Haemagglutinin C Complex: Lyophilised powder for I.M. injection 300 units, Lyophilised powder for I.M. injection 500 units; Dysport®
- Dabrafenib and Trametinib: dabrafenib: Capsule 50 mg, Capsule 75 mg; trametinib: Tablet 500 micrograms, Tablet 2 mg; Tafinlar® and Mekinist®
- Daratumumab: Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex®
- Darbepoetin Alfa: Injection 200 micrograms in 0.4 mL pre-filled syringe, Injection 300 micrograms in 0.6 mL pre-filled syringe, Injection 500 micrograms in 1 mL pre-filled syringe; Aranesp®
- Dasatinib: Tablet 20 mg, Tablet 50 mg, Tablet 70 mg, Tablet 100 mg; Sprycel®
- Drugs for the Treatment of Hepatitis C Stakeholder Meeting Outcomes December 2018 (various)
- Enoxaparin: Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe, Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe; Clexane®
- Erenumab: Injection 70 mg in 1 mL single dose pre-filled pen; Aimovig®
- Exenatide: Injection 2 mg in 0.85 mL single dose autoinjector; Bydureon® BCise®
- Fluticasone Fuorate with Umeclidinium and Vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses; Trelegy® Ellipta®
- Infliximab: Powder for I.V. infusion 100 mg; Inflectra®
- Insulin Glargine with Lixisenatide: Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 50 micrograms per mL, 3 mL, 5, Injections (human analogue), cartridges, insulin glargine 100 units per mL with lixisenatide 33 micrograms per mL, 3 mL, 5; Soliqua®
- Ivacaftor: Sachet containing granules 50 mg, Sachet containing granules 75 mg; Kalydeco®
- Lanreotide: Injection 120 mg (as acetate) in single dose pre-filled syringe; Somatuline®Autogel®
- Lenalidomide: Capsule 5 mg, Capsule 10 mg, Capsule 15 mg, Capsule 25 mg; Revlimid®
- Lenalidomide: Capsule 5 mg, Capsule 10 mg, Capsule 15 mg; Revlimid®
- Letermovir: Tablet 240 mg; Prevymis®
- Levonorgestrel: Intrauterine drug delivery system 19.5 mg; Kyleena®
- Morphine: Capsule containing morphine sulfate pentahydrate 10 mg (modified release), Capsule containing morphine sulfate pentahydrate 20 mg (modified release); Kapanol®
- Naloxone: 2.2 mg/actuation nasal spray, 2 x 1 actuation; Nyxoid®
- National Hepatitis C Data Collection (various)
- Neratinib: Tablet 40 mg; Nerlynx
- Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Nivolumab (Melanoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Ocriplasmin: Solution for intravitreal injection 0.375 mg in 0.3 mL; Jetrea® RTU
- Paclitaxel, Nanoparticle Albumin-Bound: Powder for I.V. injection containing 250 mg paclitaxel; Abraxane®
- Pegvisomant: Injection set containing powder for injection 10 mg, 30 and diluent, 30, Injection set containing powder for injection 15 mg, 30 and diluent, 30, Injection set containing powder for injection 20 mg, 30 and diluent, 30, Injection set containing powder for injection 20 mg, 1 and diluent, 1; Somavert®
- Pembrolizumab: Powder for injection 50 mg, Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; keytruda®
- Pertuzumab: Solution for I.V. infusion 420 mg in 14 mL; Perjeta®
- Quadrivalent Influenza Vaccine: 0.5 mL pre-filled syringe; Fluarix Tetra®
- Rituximab: Solution for I.V. infusion 100 mg in 10 mL, Solution for I.V. infusion 500 mg in 50 mL; Truxima®
- Rivaroxaban: Tablet 2.5 mg; Xarelto®
- Sevelamer: Tablet containing sevelamer hydrochloride 800 mg; Sevelamer Dr Reddy
- Sodium Phenylbutyrate: Granules 483 mg (as sodium) per g, 174 g; Pheburane®
- Somatropin: Powder for injection 5 mg (15 i.u.) with diluent in pre-filled pen (with preservative); Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative); Genotropin GoQuick®; Solution for injection 10 mg (30 i.u.) in 2 mL cartridge (with preservative); NutropinAq®
- Teduglutide: Powder for injection 5 mg with diluent; Revestive®
- Tenofovir with Emtricitabine and Efavirenz: Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and efavirenz 600 mg; Atripla®; Tenofovir with Emtricitabine and Rilpivirine: Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and rilpivirine 25 mg (as hydrochloride); Eviplera®; Tenofovir with Emtricitabine, Elvitegrevir and Cobicistat: Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg; Stribild®
- Tezacaftor with Ivacaftor: Tablet containing tezacaftor 100 mg with ivacaftor 150 mg; Symdeko® (F508 deletion)
- Tezacaftor with Ivacaftor: Tablet containing tezacaftor 100 mg with ivacaftor 150 mg; Symdeko® (RF mutation)
- Tiotropium: Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device); Braltus®Tiotropium: Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device); Braltus®
- Tiotropium: Capsule containing powder for oral inhalation 18 micrograms (for use in HandiHaler); Spiriva®
- Tocilizumab: Injection 162 mg in 0.9 mL single use pre-filled pen; Actemra® (GCA)
- Tocilizumab: Injection 162 mg in 0.9 mL single use pre-filled pen; Actemra® (JIA)
- Tofacitinib: Tablet 5 mg, Tablet 10 mg; Xeljanz®
- Trastuzumab: Powder for I.V. infusion 150 mg, Powder for I.V. infusion 440 mg with diluent; Ogivri®
- Trastuzumab: Powder for I.V. infusion 150 mg; Ontruzant®
- Triglycerides - Medium Chain, Formula: Oral liquid 500mL, 12 (Nutrini Peptisorb), Oral liquid 500 mL, 12 (Nutrini Peptisorb Energy); Nutrini Peptisorb®, Nutrini Peptisorb Energy®
The following Public Summary Document from the November 2018 meeting is now available.
